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Abstract
Adjuvant hormonal therapy has been demonstrated to
be able to delay disease progression in nonmetastatic
prostate cancer. To date, however, a favorable impact on
survival has only been demonstrated in lymph-node-
positive disease and in external-beam radiotherapy se-
ries with locally advanced and probably mainly micro-
metastatic tumors. The Bicalutamide Early Prostate Can-
cer Program is the largest study under way to define the
role of adjuvant treatment in early prostate cancer and
identify subgroups of patients likely to benefit from
immediate hormonal therapy. At the time of the most
recently published analysis, the risk of objective clinical
progression was significantly reduced in the bicalutam-
ide arm (hazards ratio 0.58, 95% confidence interval
0.51–0.66, p ! 0.0001). However, further maturation of
data is needed to see whether this difference will lead to
a survival advantage.
Copyright © 2003 S. Karger AG, Basel
Adjuvant Treatment for Prostate Cancer
If prostate cancer is organ confined, radical prostatec-
tomy achieves disease-specific 10-year survival rates of
about 90% [1]. There are, however, subsets of patients
with a markedly less favorable outcome. When disease
has spread outside the prostate, survival is compromised.
In a multicentric study with 298 stage cT3 patients
treated by pelvic lymph node dissection with or without
subsequent radical prostatectomy, the prostate cancer-
specific 10-year survival rate was only 57% [2]. Radio-
therapy alone for locally advanced prostate cancer pro-
duced unfavorable results as well [3]. Whereas the long-
term outcome after radical prostatectomy is excellent in
tumors with a Gleason score of 2–6, the disease-specific
15-year survival is clearly compromised when the Glea-
son score is 7–10 [4]. In the especially problematic sub-
group of patients with Gleason score 8–10 disease, dis-
ease-specific 15-year survival after radical prostatectomy
is less than 50% [4]. Several clinical trials investigated the
effect of adjuvant hormonal therapy to improve these
results. Generally, to date, a favorable impact of adjuvant
hormonal treatment on survival has only been demon-
strated in lymph-node-positive disease and in external-
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Table 1. Overview over selected studies on adjuvant hormonal treatment after curative therapy for prostate cancer
Authors Year Setting Inclusion
criteria
Hormonal
treatment
Progression Survival
Pilepich et al. [5]
Lawton et al. [6]
1997
2001
RT stage C or D1 LHRH analogues advantage for
adjuvant treatment
advantage for adjuvant treatment in
Gleason score 8–10 subgroup
Granfors et al. [7] 1998 RT T1–4N0–1 orchiectomy advantage for
adjuvant treatment
advantage for adjuvant treatment in
N1 subgroup
Arcangeli et al. [8] 1998 RT confined to
the pelvis
multiple regimens no advantage for
adjuvant treatment
disadvantage for adjuvant treatment
Hanks et al. [9] 2000 RT T2b–T4,
PSA ! 150 ng/ml
LHRH analogues
plus flutamide
advantage for
adjuvant treatment
advantage for adjuvant treatment in
high risk subsets (cT3–4 or cT2 with
Gleason score 8–10,
all Gleason score 8–10 cancers)
Bolla et al. [10] 2002 RT T1–T4N0–x LHRH analogues advantage for
adjuvant treatment
advantage for adjuvant treatment
Zincke et al. [11] 1992 RPE pN+ multiple regimens advantage for
adjuvant treatment
advantage for adjuvant treatment in
diploid subgroup
Seay et al. [12] 1998 RPE pN+ orchiectomy or
LHRH analogues
advantage for
adjuvant treatment
advantage for adjuvant treatment in
diploid subgroup after 10 years
Messing et al. [13] 1999 RPE pN+ orchiectomy or
LHRH analogues
advantage for
adjuvant treatment
advantage for adjuvant treatment
Prayer-Galetti et al. [14] 2000 RPE stage C LHRH analogues advantage for
adjuvant treatment
not available
Zincke et al. [15] 2001 RPE seminal vesicle
involvement
orchiectomy or
oral hormones
advantage for
adjuvant treatment
advantage for adjuvant treatment
Wirth et al. [16]
Wirth et al. [17]
1997
2003
RPE stage C flutamide advantage for
adjuvant treatment
no detectable difference
RT = Radiotherapy; RPE = radical prostatectomy.
beam radiotherapy series with locally advanced and prob-
ably mainly micrometastatic tumors (table 1). Adjuvant
treatment after the resection or destruction of all macro-
scopic tumor tissue is intended to prevent progression of
suspected microscopic residual cancer. During the last
decades, new means of hormonal deprivation (LHRH
analogues, antiandrogens) have been developed which
allow for reversible and time-limited treatment. Since
even in incurable locally advanced or metastatic prostate
cancer, immediate hormonal treatment offers only a small
survival advantage over deferred treatment after 10 years
– detectable only in a meta-analysis including more than
2,000 patients [18] – trials investigating the effect of adju-
vant treatment in early prostate cancer require very large
numbers of patients enrolled and a long follow-up. The
optimal duration of adjuvant treatment and the question
whether delayed onset of hormonal treatment (controlled
by PSA monitoring) may be as effective as immediate
treatment in risk patients [19] remain the subject of an
ongoing debate.
The Bicalutamide Early Prostate Cancer
Program
In early breast cancer, adjuvant treatment with the
antioestrogen tamoxifen resulted in a significant survival
benefit over local therapy only [20]. Since prostate cancer
is also a hormone-sensitive tumor, it has been hypothe-
zised that early antiandrogenic therapy may be beneficial
in this tumor entity as well [21, 22]. In the ‘Bicalutamide
Early Prostate Cancer Program’ (for clinical stages T1b-
4N0-1M0), the nonsteroidal antiandrogen bicalutamide is
being evaluated as primary or adjuvant therapy for early
prostate cancer. The program consists of three double-
blind, parallel-group trials (one in North America (trial
23, n = 3,292), one in Mexico, South Africa, Australia and
Europe (trial 24, n = 3,603), and one in Scandinavia (trial
25, n = 1,218) [22]. In trial 23, all patients underwent radi-
cal prostatectomy or radiotherapy prior to study entry. In
trials 24 and 25, watchful waiting was possible as a prima-
ry management option besides both treatments with cura-
Bicalutamide Early Prostate Cancer
Program
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Fig. 1. Freedom from objective clinical progression at 5 years [22]. Fig. 2. Freedom from biochemical progression at 5 years [22].
tive intent [21, 22]. For an exact description of the inclu-
sion and exclusion criteria, see See et al. [22]. With a total
of 8,113 patients, this program is the largest currently
ongoing study on prostate cancer [23]. The patients were
randomized on a 1:1 basis to receive either bicalutamide
150 mg once daily (n = 4,052) or placebo (n = 4,061) [22].
In North America, more than 80% had undergone radical
prostatectomy and 20% received radiotherapy prior to
randomization, compared to 46 and 18% in the Mexico,
South Africa, Australia and Europe trial and 13 and 5% in
the Scandinavian trial [22]. In North America, more than
70% of patients entered had a tumor stage of less than T3,
compared with approximately 60% in Europe and Scan-
dinavia [22–24]. The patients received the adjuvant med-
ication for 2 or more years [22]. Time to objective clinical
progression (defined as tumor progression confirmed by
either biopsy, bone scan, computerized tomography, ul-
trasound, or magnetic resonance imaging or death of any
causes) and survival are the primary end points in the
Bicalutamide Early Prostate Cancer Program [21, 22].
Time to treatment failure (withdrawal from treatment),
PSA progression (defined as doubling of the PSA value
measured immediately prior to the initiation of the appli-
cation of the study medication) and tolerability are sec-
ondary end points [21, 22]. After a median follow-up of 3
years, 38.1% of patients in the bicalutamide group and
31.8% in the placebo group discontinued the treatment.
Adverse events were the most common reason for with-
drawal from treatment in the bicalutamide group versus
disease progression in the placebo group [22]. Gyneco-
mastia and/or breast pain were the most frequent adverse
events in the bicalutamide arm with almost 3 of 4 patients
being affected [22]. These symptoms improved or re-
solved after withdrawal of treatment in the majority of
cases. Whereas breast pain disappeared in 84% of affected
patients within 1 year after cessation of therapy, the reso-
lution rate of gynecomastia depended on the duration of
bicalutamide treatment with only 29% resolution in those
patients who took the medication for more than 18
months [22]. At the time of the most recently published
analysis [22], 363 patients in the bicalutamide arm and
559 patients in the placebo arm fulfilled the criteria of
objective clinical progression (fig. 1). This reduction in
the risk of clinical progression by 45% in the bicalutamide
arm was highly significant (hazards ratio 0.58, 95% confi-
dence interval 0.51–0.66, p ! 0.0001). This result needs to
be qualified by emphasizing that in trial 23, with its much
more favorable risk profile, there was no detectable differ-
ence concerning objective progression at this time (83
events in the bicalutamide arm and 87 events in the place-
bo arm). Overall, the reduction in the risk was observed in
the whole study population regardless of the primary (cu-
rative or noncurative) treatment. Subgroup analyses re-
vealed a hazards ratio of 0.63 (p ! 0.001) for patients who
had radical prostatectomy or radiotherapy and of 0.53
(p ! 0.001) for those who did not undergo curative treat-
ment [22]. As expected, the risk reduction was greater in
patients with locally advanced disease and in those select-
ed for watchful waiting [22]. Not unexpectedly, consid-
ering PSA progression, there was also a highly significant
advantage in the bicalutamide arm (fig. 2). For a survival
analysis, however, there were too few events observed up
to the time of analysis, and a longer follow-up is needed to
see whether the delayed clinical progression in the bicalu-
tamide arm will translate into a survival advantage which
is the most urgent question to be answered.
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Conclusion
Adjuvant treatment for prostate cancer has been
shown to provide a survival advantage in patients with
histopathologically proven lymph node involvement or
with a high risk of microscopic spread. It is, however, still
controversial whether a slightly delayed treatment (onset
at PSA relapse) may be equally effective. Except for the
above-mentioned high-risk patients, randomized trials on
adjuvant treatment have so far revealed a delay of pro-
gression but no survival advantage in early prostate can-
cer. The maturation of data of large ongoing trials like the
Bicalutamide Early Prostate Cancer Program will in-
crease our knowledge base. However, further studies
investigating the appropriate length of adjuvant hormon-
al therapy are also needed. Efforts are necessary to im-
prove our understanding of factors influencing the surviv-
al of men with early prostate cancer.
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